

Barcelona, March 2nd 2020

DISCLOSURE OF OTHER RELEVANT INFORMATION

Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin in actinic keratosis

Almirall, S.A. (ALM.MC), in compliance with the provisions of article 227 of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, hereby notifies the National Securities Market Commission of the following:

Almirall today announced that the European Medicines Agency's (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis.

If approved by the EMA, tirbanibulin could be an important step forward to actinic keratosis treatment in Europe, as it has the potential to provide a marked improvement of the quality of life for patients suffering from this disease.

It is estimated that peak sales of tirbanibulin will be in excess of €250 million in Europe and in the US.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com